Elypta Drops Data Showing Power Of Metabolite-Based MCED Test
Executive Summary
Elypta’s MIRAM kit for multi-cancer early detection performed well in a large-scale study.
You may also be interested in...
Leading The Way From A Singular Position - An IWD Perspective
Anne Osdoit has learned how to transform what would be challenges in her career into sources of inspiration. With this vital skill, she has not only led her company, Moon Surgical, to success, but also aided Sofinnova, where she serves as partner, in its investment strategy.
Sex-Based Diversity In Clinical Trials Can And Will Improve – An IWD Perspective
As a three-time cancer survivor and someone who has participated in a device trial, Alicia Staley, Medidata’s VP of patient engagement, is no stranger to innovative treatments. She spoke to Medtech Insight about how both the gender and socioeconomic diversity of trial participants could be improved.
'Who Cares?' Ablatus’ CEO On Why Improvements To Women’s Health Will Benefit Everyone
Fibroids are an issue that can be debilitating for women, however funding of new treatments for them is abysmal. Medtech Insight spoke to Chung Looi, CEO of Ablatus, about this valuable market, and why women’s health is so often overlooked, and how its solution could have an impact.